About this trial
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)
Disqualifiers
Patients who lack decisional capacity
Patients unable to read/speak English
Patients who are on a blood thinner (anticoagulation medication)
Patients who do not have internet access to complete postoperative surveys
Trial design
Parallel
Treatments tested in this trial
Magneto 150 holmium laser
DeviceThe HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser
Moses 2.0 holmium laser
DeviceThe HoLEP procedure will be performed using the Moses 2.0 holmium laser
Treatment groups
Trial outcomes
Primary outcomes
Mean hemostasis time
Overall intraoperative hemostasis time
Secondary outcomes
Mean (average) enucleation time
Time taken to surgically remove excess prostate tissue while leaving the shell of the prostate intact and within the body.
Total operative time
Time taken from official procedure start to completion (not accounting for the time that the patient is wheeled in, prepped and out of the operating room).
Hemostasis efficiency
minutes/gram (prostate tissue removed)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Northwestern University
Lead sponsor
Cook Group Incorporated
Collaborator